MS Blood Test: What GFAP Adds to Multiple Sclerosis Monitoring

An MS blood test is not yet a way to diagnose multiple sclerosis, but it is quickly becoming a way to follow it. A study published in JAMA Neurology in August 2026 tracked a protein called GFAP in more than 2,300 people with multiple sclerosis and found that its level in blood was linked to the slow, silent worsening that happens between relapses. In this article you’ll learn what GFAP measures, how it differs from the neurofilament marker already used in research, what these results do and do not prove, and which questions are worth raising at your next neurology appointment.

What the August 2026 study actually measured

Researchers at the University of Basel and the University of California, San Francisco pooled two long-running patient groups: the Swiss MS Cohort and the EPIC study in San Francisco. Together they covered 2,329 people and more than 18,600 blood measurements, some participants followed for over a decade. Every six to twelve months, two proteins were measured from a standard blood draw: GFAP (glial fibrillary acidic protein) and NfL (neurofilament light chain).

The question was narrow and practical. Could either protein anticipate progression independent of relapse activity, the medical term for disability that creeps upward without an obvious attack? GFAP could. People whose GFAP was high for their age were around 40% more likely to worsen before their next scheduled visit. And when GFAP fell over the first two years of treatment, the risk of later worsening dropped substantially.

The authors also noted a research use: selecting participants by GFAP could shrink the size of clinical trials aimed at progression by roughly a fifth, which matters because progressive forms of the disease are the hardest to study.

GFAP and NfL describe two different things

The two proteins are often named in the same breath, but they come from different cells and carry different messages. NfL leaks out of damaged nerve fibers, so it rises during and around a relapse. GFAP comes from astrocytes, the support cells of the brain and spinal cord, and it tracks the slower background process rather than the acute flare.

That complementarity is the practical point. Used together, the two markers describe different halves of the same disease, which is why current research measures both rather than choosing one.

What this changes for you, and what it does not

Three points deserve to be stated plainly.

First, this is a monitoring marker, not a screening test. GFAP rises in many conditions that injure the brain, and it also climbs naturally with age. A single raw value in isolation means very little, which is why the researchers worked with age-adjusted scores rather than plain numbers.

Second, multiple sclerosis is still diagnosed the same way it was last year. Our overview describes multiple sclerosis symptoms, causes and diagnosis. The diagnosis rests on the clinical picture, MRI findings and, where needed, spinal fluid analysis. No blood protein replaces that.

Third, GFAP is not yet part of routine care in most countries. The assays used in these cohorts are ultrasensitive research platforms, and no agreed threshold exists that a laboratory could print on your report today. If your neurologist mentions GFAP, it will usually be in the context of a study or a specialist center.

What does change is the conversation. Until now, silent progression was mostly recognized in hindsight, once function had already slipped. A marker that shifts before the walking test does gives clinicians something earlier to react to.

최신 과학적 발전

Four publications from the past three years explain how GFAP moved from a laboratory curiosity to a credible monitoring tool.

In 2023, a Swiss team compared GFAP and NfL head to head in 355 people. They found that patients with worsening progressive disease had clearly higher GFAP than stable patients, even after accounting for NfL, and that higher GFAP went along with faster loss of gray matter on MRI. What this means for you: the two markers were already telling different stories, and GFAP was the one linked to steady decline rather than to flares.

In 2024, the same group followed 362 people starting a B-cell depleting treatment, one of the strong immune therapies used in multiple sclerosis. Those whose GFAP stayed high a year after starting were more likely to worsen afterwards. What this means for you: the marker seems to respond to treatment, not just to disease, which is what makes it useful for follow-up.

A 2025 review in The Lancet Neurology set out where these blood markers stand. NfL reflects damage to nerve fibers during active inflammation; GFAP is described as an emerging marker of progression independent of relapses; a third protein, CHI3L1, is under study. What this means for you: the field is converging on a panel of several markers rather than one perfect test.

The August 2026 study is the largest of the four and the first with independent validation in a second, separate cohort. That matters: a result that holds up in a different country, with different patients and different clinicians, is far more trustworthy than one that appears only once. Still, all four are observational studies, which show associations rather than prove cause and effect, and none of them established a cut-off value that a clinic can apply to an individual patient today.

When to talk to your neurologist

Blood markers are a research topic, but the reasons to seek review are unchanged and concrete:

• New or worsening weakness, numbness, vision loss or balance problems lasting more than 24 hours
• A gradual change over months in walking distance, hand dexterity or fatigue, even without a clear attack
• Side effects or blood count changes while on a disease-modifying therapy
• Uncertainty about whether your current treatment is still working

Routine laboratory monitoring already accompanies most MS therapies, and understanding it helps. A separate guide explains 혈액 검사 결과 읽는 법 가이드, 또 다른 가이드에서는 비정상 혈액 검사 결과. If you are new to testing, we also describe 혈액 검사 중 어떤 일이 일어나는가.

Because multiple sclerosis is an immune-mediated condition, related pages may help too. One article reviews autoimmune disease symptoms and treatments, another details the autoimmune panel, 그리고 세 번째 항목에서는 CRP 수치 상승.

용어 설명

자주 묻는 질문

Can a blood test diagnose multiple sclerosis?

No. There is no single blood test that confirms multiple sclerosis. Diagnosis combines the clinical history, a neurological examination, MRI of the brain and spinal cord, and sometimes analysis of cerebrospinal fluid obtained by lumbar puncture. Blood tests are mainly used to rule out conditions that mimic MS, such as certain infections, vitamin deficiencies and other autoimmune diseases.

Can I ask my doctor for a GFAP test?

In most countries the answer today is no, because the test is not routinely offered outside research settings and no validated reference threshold exists for individual decisions. Specialist MS centers taking part in studies may measure it. It is reasonable to ask your neurologist whether your center participates in biomarker research.

Does a high GFAP mean my MS is getting worse?

Not on its own. The 2026 study reported a higher average risk across a large group, not a certainty for any one person. GFAP also rises with age, differs between men and women, and increases after other brain injuries such as stroke or head trauma. It is one signal among many, interpreted alongside symptoms and imaging.

Is this the same as the new Alzheimer’s blood tests?

No, although both belong to the same family of ultrasensitive blood assays. Alzheimer’s tests measure proteins such as p-tau217 that relate to amyloid and tau pathology. GFAP and NfL are general markers of brain and nerve injury and are studied across several neurological conditions.

Do MS treatments require regular blood tests?

Yes, most disease-modifying therapies require periodic monitoring, typically a complete blood count, liver enzymes and sometimes kidney function, at intervals set by the medicine you take. This is separate from biomarker research and is part of standard safety follow-up.

How long do these results take to come back?

Routine safety tests are usually available within one to three working days. Research assays such as GFAP are run in batches and may take weeks, which is another reason they are not currently used for immediate clinical decisions.

출처

• National Library of Medicine — Multiple Sclerosis, MedlinePlus, 2026 — medlineplus.gov
• National Institute of Neurological Disorders and Stroke — Multiple Sclerosis (MS), NIH, 2025 — ninds.nih.gov
• Mayo Clinic — Multiple sclerosis: diagnosis and treatment, 2026 — mayoclinic.org
• Einsiedler M, Sandgren S, Schaedelin S, et al. — Serum Glial Fibrillary Acidic Protein Dynamics, Disease Progression, and Therapy Response in Multiple Sclerosis — JAMA Neurology, 2026 — doi.org/10.1001/jamaneurol.2026.2500
• Meier S, Willemse EAJ, Schaedelin S, et al. — Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis — JAMA Neurology, 2023 — doi.org/10.1001/jamaneurol.2022.5250
• Benkert P, et al. — Serum GFAP and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis — Annals of Neurology, 2024 — consensus.app
• Chitnis T, Magliozzi R, Abdelhak A, et al. — Blood and CSF biomarkers for multiple sclerosis: emerging clinical applications — The Lancet Neurology, 2025 — doi.org/10.1016/S1474-4422(25)00249-2

추가 읽을거리

• 전혈구검사(CBC): 결과 읽는 법
• 정상 혈액 검사 수치 설명
• 혈액 검사 결과가 나오기까지 걸리는 시간
• 종합 혈액 검사: 정말 필요한 걸까요?
• 혈액검사 전 공복: 규칙과 시간

AI DiagMe로 내 검사 결과 이해하기

Living with a neurological condition often means repeated laboratory monitoring: blood counts, liver enzymes, kidney function, vitamin D. Those numbers are easy to collect and hard to interpret alone. AI DiagMe reads your results, explains what each value means in plain language and shows how it compares with reference ranges. It helps you understand and prepare your questions; it does not diagnose, and it does not replace your doctor.

몇 분 안에 내 검사 결과 해석받기